151 related articles for article (PubMed ID: 11416951)
1. Galantamine introduced in Europe.
Am J Alzheimers Dis Other Demen; 2001; 16(1):8. PubMed ID: 11416951
[No Abstract] [Full Text] [Related]
2. [Galantamine].
Taéron C
Rev Infirm; 2008 Sep; (143):44-6. PubMed ID: 18788671
[No Abstract] [Full Text] [Related]
3. Rationale for combination therapy with galantamine and memantine in Alzheimer's disease.
Grossberg GT; Edwards KR; Zhao Q
J Clin Pharmacol; 2006 Jul; 46(7 Suppl 1):17S-26S. PubMed ID: 16809811
[TBL] [Abstract][Full Text] [Related]
4. Galantamine--a novel cholinergic drug with a unique dual mode of action for the treatment of patients with Alzheimer's disease.
Lilienfeld S
CNS Drug Rev; 2002; 8(2):159-76. PubMed ID: 12177686
[TBL] [Abstract][Full Text] [Related]
5. Galantamine for Alzheimer's disease and mild cognitive impairment.
Cusi C; Cantisani TA; Celani MG; Incorvaia B; Righetti E; Candelise L;
Neuroepidemiology; 2007; 28(2):116-7. PubMed ID: 17409773
[No Abstract] [Full Text] [Related]
6. The clinical efficacy and safety of galantamine in the treatment of Alzheimer's disease.
Dengiz AN; Kershaw P
CNS Spectr; 2004 May; 9(5):377-92. PubMed ID: 15115951
[TBL] [Abstract][Full Text] [Related]
7. [Nicotinic Receptor, galantamine and Alzheimer disease].
Arroyo G; Aldea M; Fuentealba J; García AG
Rev Neurol; 2002 Jun 1-15; 34(11):1057-65. PubMed ID: 12134305
[TBL] [Abstract][Full Text] [Related]
8. An update on the pharmacology of galantamine.
Villarroya M; García AG; Marco-Contelles J; López MG
Expert Opin Investig Drugs; 2007 Dec; 16(12):1987-98. PubMed ID: 18042006
[TBL] [Abstract][Full Text] [Related]
9. Galantamine: a new alzheimer drug with a past life.
Pearson VE
Ann Pharmacother; 2001 Nov; 35(11):1406-13. PubMed ID: 11724094
[TBL] [Abstract][Full Text] [Related]
10. Metabolic patterns associated with the clinical response to galantamine therapy: a fludeoxyglucose f 18 positron emission tomographic study.
Mega MS; Dinov ID; Porter V; Chow G; Reback E; Davoodi P; O'Connor SM; Carter MF; Amezcua H; Cummings JL
Arch Neurol; 2005 May; 62(5):721-8. PubMed ID: 15883258
[TBL] [Abstract][Full Text] [Related]
11. [Mechanisms of action of Alzheimer medications].
Alhainen K
Duodecim; 2003; 119(20):1959-66. PubMed ID: 14640001
[No Abstract] [Full Text] [Related]
12. The efficacy of galantamine in the treatment of Alzheimer's disease: comparison of patients previously treated with acetylcholinesterase inhibitors to patients with no prior exposure.
Mintzer JE; Kershaw P
Int J Geriatr Psychiatry; 2003 Apr; 18(4):292-7. PubMed ID: 12673604
[TBL] [Abstract][Full Text] [Related]
13. A comparison of donepezil and galantamine in the treatment of cognitive symptoms of Alzheimer's disease: a meta-analysis.
Harry RD; Zakzanis KK
Hum Psychopharmacol; 2005 Apr; 20(3):183-7. PubMed ID: 15700322
[TBL] [Abstract][Full Text] [Related]
14. Update on Alzheimer drugs (galantamine).
Raskind MA
Neurologist; 2003 Sep; 9(5):235-40. PubMed ID: 12971834
[TBL] [Abstract][Full Text] [Related]
15. The SERAD study of the safety and efficacy of galantamine in severe Alzheimer's disease.
Farlow MR
Lancet Neurol; 2009 Jan; 8(1):22-3. PubMed ID: 19042160
[No Abstract] [Full Text] [Related]
16. [Pharmacotherapy of a patient with Alzheimer's disease: interactions with the antidementive galantamine].
Schwalbe O; Wunderlich S; Kloft C
Med Monatsschr Pharm; 2006 Jun; 29(6):222-4. PubMed ID: 16792199
[TBL] [Abstract][Full Text] [Related]
17. Effect of galantamine on verbal repetition in AD: a secondary analysis of the VISTA trial.
Wong VS
Neurology; 2007 Aug; 69(8):809; author reply 809-10. PubMed ID: 17709718
[No Abstract] [Full Text] [Related]
18. Galantamine improves gait performance in patients with Alzheimer's disease.
Assal F; Allali G; Kressig RW; Herrmann FR; Beauchet O
J Am Geriatr Soc; 2008 May; 56(5):946-7. PubMed ID: 18454755
[No Abstract] [Full Text] [Related]
19. An unusual case of nightmares with galantamine.
Iraqi A; Hughes TL
J Am Geriatr Soc; 2009 Mar; 57(3):565. PubMed ID: 19278402
[No Abstract] [Full Text] [Related]
20. Galantamine treatment in Alzheimer's disease with cerebrovascular disease: responder analyses from a randomized, controlled trial (GAL-INT-6).
Erkinjuntti T; Gauthier S; Bullock R; Kurz A; Hammond G; Schwalen S; Zhu Y; Brashear R
J Psychopharmacol; 2008 Sep; 22(7):761-8. PubMed ID: 18308781
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
